Pemetrexed has now been recommended for the first-line treatment of non-small-cell lung cancer (see NICE technology appraisal guidance 181). NICE technology appraisal guidance 124 applies to patients who have had prior chemotherapy.

  • Pemetrexed is not recommended for the treatment of locally advanced or metastatic non-small-cell lung cancer.
  • People currently receiving pemetrexed should have the option to continue therapy until they and their clinicians consider it appropriate to stop.